Abstract: Compounds of formula (I) are made, wherein W1, W2, W3, W4, R1, R2, R3, R4, R5, R6 and m have the meaning as described herein. The compounds are SRPK inhibitors and can be used, inter alia, for the treatment of hyperproliferative disorders. A medicament and a pharmaceutical composition are made that include the compound of formula (I). Methods are developed for treating a disease caused, mediated, and/or propagated by SRPK activity, for preparing a medicament for the treatment thereof, and for inhibiting SRPK.

Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: Compounds of the formula I in which R1 denotes A, Ar, Cyc, Het, COA or CN, R2 denotes SO2A, SOA, SA, SO2NHA, SO2NA2, S(?NH,?O)A, S(?NH)2A, NO2, Hal, CN, A, Het1, COOH or COOA, R3 denotes H or Hal, R4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2?, and can be employed for the treatment of diseases such as cancer.

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof: